title: Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
abstract: Two studies were conducted in subjects with mild or moderate hepatic or renal impairment and subjects with normal organ function to evaluate the pharmacokinetics of casopitant and to assess its safety in these populations. A total of 26 subjects were enrolled in the hepatic impairment study and 18 subjects in the renal impairment study. All subjects received oral casopitant 100 mg once-daily for 5 days. Casopitant area under the concentration-time curve (AUC) increased 11% and 24% in subjects with mild or moderate hepatic impairment, respectively, on Day 1, compared with subjects with normal hepatic function; a similar increase was observed on Day 5. The AUC of the active major metabolite, GSK525060, was reduced 29% and 19% on Days 1 and 5, respectively, in subjects with moderate hepatic impairment, but not altered by mild hepatic impairment. Casopitant AUC increased 34% and 22% on Day 1 in subjects with mild or moderate renal impairment, respectively, and 28% and 11% on Day 5, respectively, compared with subjects with normal renal function. GSK525060 AUC was increased 17% and 24% on Days 1 and 5, respectively, in subjects with mild renal impairment; but did not significantly change in subjects with moderate renal impairment. Further age-adjusted analysis showed no meaningful effect of renal impairment on casopitant or GSK525060 AUC. Plasma protein binding of casopitant and GSK525060 was similar in all subjects. The pharmacokinetics of casopitant is not altered to a clinically significant extent in subjects with mild or moderate, hepatic or renal impairment. The impact of severe hepatic or renal impairment was not evaluated.
authors.affiliation: Discovery Operations & Clinical Sciences, GlaxoSmithKline, Inc, Research Triangle Park, NC, USA. John.W.Bauman@gsk.com
authors.forename: John W
authors.initials: JW
authors.lastname: Bauman
authors.forename: Joyce M
authors.initials: JM
authors.lastname: Antal
authors.forename: Laurel M
authors.initials: LM
authors.lastname: Adams
authors.forename: Brendan M
authors.initials: BM
authors.lastname: Johnson
authors.forename: Sharon C
authors.initials: SC
authors.lastname: Murray
authors.forename: Bin
authors.initials: B
authors.lastname: Peng
authors.forename: Lyndon C
authors.initials: LC
authors.lastname: Kirby
authors.forename: Peter F
authors.initials: PF
authors.lastname: Lebowitz
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Marbury
authors.forename: Suzanne
authors.initials: S
authors.lastname: Swan
authors.forename: Maria
authors.initials: M
authors.lastname: Gutierrez
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001711:Biotransformation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000378:metabolism*; D016018:Least-Squares Analysis; D008107:Liver Diseases / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D064729:Neurokinin-1 Receptor Antagonists; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D011485:Protein Binding; D012720:Severity of Illness Index; D014481:United States; D014508:Urea
chemical_list: D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists; D010879:Piperazines; D010880:Piperidines; C531951:casopitant; D014508:Urea